SYN Stock Overview
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.
+ 2 more risks
Synthetic Biologics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.04|
|52 Week High||US$4.95|
|52 Week Low||US$1.03|
|1 Month Change||-31.58%|
|3 Month Change||-48.00%|
|1 Year Change||-78.78%|
|3 Year Change||-77.08%|
|5 Year Change||-99.68%|
|Change since IPO||-99.82%|
Recent News & Updates
|SYN||US Biotechs||US Market|
Return vs Industry: SYN underperformed the US Biotechs industry which returned -30% over the past year.
Return vs Market: SYN underperformed the US Market which returned -23% over the past year.
|SYN Average Weekly Movement||11.5%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: SYN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: SYN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.
Synthetic Biologics, Inc. Fundamentals Summary
|SYN fundamental statistics|
Is SYN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SYN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.12|
|Net Profit Margin||0.00%|
How did SYN perform over the long term?See historical performance and comparison